ATE260912T1 - Oxazol ppar antagonisten - Google Patents

Oxazol ppar antagonisten

Info

Publication number: ATE260912T1
Authority: AT; Austria
Prior art keywords: agonist; lxr; propyl; ppar; formula
Prior art date: 1999-09-08

Application number

AT00959913T

Other languages

English (en)

Inventor

Jeffrey Edmond Cobb

Barry George Shearer

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-08

Filing date

2000-09-01

Publication date

2004-03-15

2000-09-01 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-03-15 Application granted granted Critical

2004-03-15 Publication of ATE260912T1 publication Critical patent/ATE260912T1/de

Links

102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 3
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title abstract 3
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
239000000556 agonist Substances 0.000 abstract 4
102100038495 Bile acid receptor Human genes 0.000 abstract 2
101000603876 Homo sapiens Bile acid receptor Proteins 0.000 abstract 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
101150095442 Nr1h2 gene Proteins 0.000 abstract 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
230000004913 activation Effects 0.000 abstract 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
102000004311 liver X receptors Human genes 0.000 abstract 2
108090000865 liver X receptors Proteins 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
102000005962 receptors Human genes 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 2
102000000536 PPAR gamma Human genes 0.000 abstract 1
108010016731 PPAR gamma Proteins 0.000 abstract 1
229940125388 beta agonist Drugs 0.000 abstract 1
239000002876 beta blocker Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
238000007385 chemical modification Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
238000009510 drug design Methods 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT00959913T 1999-09-08 2000-09-01 Oxazol ppar antagonisten ATE260912T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15276199P	1999-09-08	1999-09-08
US19996900P	2000-04-27	2000-04-27
PCT/US2000/024364 WO2001017994A1 (en)	1999-09-08	2000-09-01	Oxazole ppar antagonists

Publications (1)

Publication Number	Publication Date
ATE260912T1 true ATE260912T1 (de)	2004-03-15

Family

ID=26849844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00959913T ATE260912T1 (de)	1999-09-08	2000-09-01	Oxazol ppar antagonisten

Country Status (8)

Country	Link
US (1)	US6506781B1 (de)
EP (1)	EP1210345B1 (de)
JP (1)	JP2003508529A (de)
AT (1)	ATE260912T1 (de)
AU (1)	AU7115300A (de)
DE (1)	DE60008763T2 (de)
ES (1)	ES2215719T3 (de)
WO (1)	WO2001017994A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
GB0101933D0 (en) *	2001-01-25	2001-03-07	Astrazeneca Ab	Therapy
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr)	2001-01-26	2010-12-31	Schering Corporation	Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
PT1355644E (pt)	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
EP1911462A3 (de)	2001-01-26	2011-11-30	Schering Corporation	Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US7241785B2 (en)	2001-03-23	2007-07-10	Takeda Pharmaceutical Company Limited	Five-membered heterocyclic alkanoic acid derivative
ATE480236T1 (de) *	2001-04-25	2010-09-15	Takeda Pharmaceutical	Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
US20030092736A1 (en) *	2001-05-30	2003-05-15	Cheng Peter T.	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) *	2001-05-30	2005-11-22	Bristol-Myers Squibb Company	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
KR20040044515A (ko) *	2001-08-29	2004-05-28	워너-램버트 캄파니 엘엘씨	경구용 항당뇨병제
US6869975B2 (en)	2001-09-14	2005-03-22	Tularik Inc.	Linked biaryl compounds
EP1429756B1 (de)	2001-09-21	2006-11-22	Schering Corporation	Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
GB2381866A (en) *	2001-11-12	2003-05-14	Karobio Ab	Assays for liver X receptor (LXR) modulators
WO2003043997A1 (en) *	2001-11-15	2003-05-30	Eli Lilly And Company	Peroxisome proliferator activated receptor alpha agonists
US6696473B2 (en)	2001-12-21	2004-02-24	X-Ceptor Therapeutics, Inc.	Heterocyclic modulators of nuclear receptors
US6870466B2 (en) *	2002-04-03	2005-03-22	Hewlett-Packard Development Company, L.P.	Data display system and method for an object traversing a circuit
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
US6790929B2 (en)	2002-06-12	2004-09-14	General Electric Company	Method for making an aromatic polycarbonate
ATE543497T1 (de) *	2002-07-09	2012-02-15	Bristol Myers Squibb Co	Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren
US7137963B2 (en) *	2002-08-26	2006-11-21	Flowcardia, Inc.	Ultrasound catheter for disrupting blood vessel obstructions
AU2003262023A1 (en)	2002-09-10	2004-04-30	Takeda Pharmaceutical Company Limited	Five-membered heterocyclic compounds
JP2006508188A (ja)	2002-11-06	2006-03-09	シェーリング　コーポレイション	脱髄の処置のためのコレステロール吸収インヒビター
WO2004066963A2 (en) *	2003-01-17	2004-08-12	Merck & Co., Inc.	N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
EP1587822A4 (de) *	2003-01-22	2006-04-19	Merck & Co Inc	Peroxisomenproliferatoraktivierter rezeptor
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de)	2003-03-07	2008-10-09	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US6987118B2 (en)	2003-05-21	2006-01-17	Pfizer Inc.	Tetrahydroisoquinoline derivatives as PPAR-alpha activators
KR20060135854A (ko)	2004-04-01	2006-12-29	아벤티스 파마슈티칼스 인크.	Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온
BRPI0508180A (pt) *	2004-04-01	2007-08-07	Aventis Pharma Inc	1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste
CN100467456C (zh) *	2004-05-24	2009-03-11	北京摩力克科技有限公司	作为hPPARα和/或hPPARγ激活剂的α-哌嗪取代的苯丙酸衍生物
CN100436430C (zh) *	2004-05-24	2008-11-26	北京摩力克科技有限公司	作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
ES2343640T3 (es) *	2004-08-12	2010-08-05	Amgen Inc.	Bisaril-sulfonamidas.
US20070142326A1 (en) *	2004-09-30	2007-06-21	Youe-Kong Shue	Treatment of a condition in a mammal with administration of aminosugar and uses thereof
EP1810689A4 (de) *	2004-10-15	2009-07-22	Mitsubishi Tanabe Pharma Corp	Mittel zur prävention und/oder behandlung von diabetes
WO2006044961A1 (en) *	2004-10-20	2006-04-27	Smithkline Beecham Corporation	Ppar-gamma modulatores
PL371841A1 (pl)	2004-12-20	2006-06-26	ADAMED Sp.z o.o.	Nowe związki pochodne kwasu 3-fenylopropionowego
PL372332A1 (pl)	2005-01-19	2006-07-24	ADAMED Sp.z o.o.	Nowe związki, pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl)	2005-01-20	2006-07-24	ADAMED Sp.z o.o.	Nowe związki, pochodne kwasu 3-fenylopropionowego
US20100196509A1 (en)	2005-02-28	2010-08-05	Jonathan Braun	Methods for Diagnosis and Treatment of Endometrial Cancer
WO2006113526A2 (en)	2005-04-15	2006-10-26	The Regents Of The University Of California	Prevention of chlamydia infection using a protective antibody
US8318906B2 (en)	2005-04-15	2012-11-27	The Regents Of The University Of California	EMP2 antibodies and their therapeutic uses
US8648052B2 (en) *	2005-04-15	2014-02-11	The Regents Of The University Of California	Prevention of chlamydia infection using SIRNA
CA2781290A1 (en)	2009-11-20	2011-05-26	Lynn K. Gordon	Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
PL3043865T3 (pl)	2013-09-11	2021-07-05	Institut National De La Santé Et De La Recherche Médicale (Inserm)	SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
US20160199364A1 (en) *	2015-01-13	2016-07-14	Creighton University	Seizure treatment compositions and methods
CN106146483A (zh) *	2015-04-23	2016-11-23	上海迪诺医药科技有限公司	杂环类法尼酯衍生物x受体调节剂
US20210085662A1 (en)	2017-03-30	2021-03-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses

2000
- 2000-09-01 AT AT00959913T patent/ATE260912T1/de not_active IP Right Cessation
- 2000-09-01 WO PCT/US2000/024364 patent/WO2001017994A1/en not_active Ceased
- 2000-09-01 US US10/070,474 patent/US6506781B1/en not_active Expired - Fee Related
- 2000-09-01 EP EP00959913A patent/EP1210345B1/de not_active Expired - Lifetime
- 2000-09-01 AU AU71153/00A patent/AU7115300A/en not_active Abandoned
- 2000-09-01 DE DE60008763T patent/DE60008763T2/de not_active Expired - Fee Related
- 2000-09-01 JP JP2001522217A patent/JP2003508529A/ja not_active Withdrawn
- 2000-09-01 ES ES00959913T patent/ES2215719T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2215719T3 (es)	2004-10-16
AU7115300A (en)	2001-04-10
DE60008763D1 (de)	2004-04-08
WO2001017994A1 (en)	2001-03-15
EP1210345B1 (de)	2004-03-03
US6506781B1 (en)	2003-01-14
JP2003508529A (ja)	2003-03-04
DE60008763T2 (de)	2005-02-10
EP1210345A1 (de)	2002-06-05

Legal Events

Date	Code	Title	Description
2004-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60008763D1 (de)	2004-04-08	Oxazol ppar antagonisten
DK1173433T3 (da)	2006-05-15	Cyanopyrroler som progesteronreceptoragonister
NO20014479D0 (no)	2001-09-14	Fremgangsmåte ved behandling av spiseforstyrrelser
HUP0303339A2 (hu)	2004-01-28	Heteroaril-karbamid neuropeptid Y Y5 receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
NO20003671L (no)	2000-09-18	4-(2-keto-1-benzimidazolinyl)piperidin-forbindelser som orl1- reseptor agonister
MY141559A (en)	2010-05-14	Triazole derivatives as tachykinin receptor antagonists
JP2004532209A5 (de)	2005-12-22
CO5611063A2 (es)	2006-02-28	Pirazolilcarboxanilidas disubstituidas
DE69619479D1 (de)	2002-04-04	Azaheterocyclische Tachykinin Rezeptor Antagoniste; NK1 und NK2
RU2007121850A (ru)	2008-12-20	Производные фосфонооксихиназолина и их фармацевтическое применение
BR9508292A (pt)	1997-12-23	Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
DE60218703D1 (de)	2007-04-19	(-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
MY146532A (en)	2012-08-15	Thiazole derivative
ATE496620T1 (de)	2011-02-15	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
UA72917C2 (en)	2005-05-16	Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
SE9900274D0 (sv)	1999-01-28	New compound
WO2004013101A3 (fr)	2004-05-13	Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP1625123A4 (de)	2007-08-29	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazole als s1p-rezeptoragonisten
NO992226D0 (no)	1999-05-07	Nye forbindelser for anvendelse som neuro-protektive midler
DK1487424T3 (da)	2007-01-08	4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)-pyrimidin-2-yl-amino)phenyl-benzamid til behandling af Ang II-medierede sygdomme
EE200100520A (et)	2002-12-16	N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
NO20042257L (no)	2004-06-24	Fremgangsmate for behandling av depresjon med deltareseptoragonistforbindelser
DK0925295T3 (da)	2002-01-28	Derivater af N-benzensulfonyl-L-prolin som antagonister af receptoren B2 for bradykinin
HK1049486A1 (zh)	2003-05-16	作為mcp-1受體拮抗劑的吲類衍生物
EA200300850A1 (ru)	2004-06-24	Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах